Reports Q2 revenue $158.81M, consensus $154.2M. “With the first half of 2025 complete, I am pleased to report continued progress towards our clinical, regulatory and commercial milestones. In Q2, we grew our glioblastoma and non-small cell lung cancer businesses and advanced our efforts to bring Tumor Treating Fields therapy to new patient populations,” said Ashley Cordova, CEO, Novocure (NVCR). “With one launch ongoing and two more on the horizon, we are well-positioned in both the near and long term. This is a pivotal period for Novocure.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- NVCR Earnings this Week: How Will it Perform?
- Ladenburg starts Novocure with a Buy, sees ‘path to profitability’
- Novocure initiated with a Buy at Ladenburg
- Promising Phase 3 Results for NovoCure’s TTFields Therapy in Pancreatic Cancer
- Novocure to present final secondary endpoint results from PANOVA-3 trial